154 related articles for article (PubMed ID: 37769330)
41. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
42. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
43. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
[TBL] [Abstract][Full Text] [Related]
44. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
45. Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC.
Chung WP; Yang CT; Yang SR; Su CY; Su HW; Liu SY; Ou HT
Front Oncol; 2022; 12():1022994. PubMed ID: 36761415
[TBL] [Abstract][Full Text] [Related]
46. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
47. Effect of postmastectomy radiotherapy on pT1-2N1 breast cancer patients with different molecular subtypes: A real-world study based on the inverse probability of treatment weighting method.
Ye S; Hu W
Medicine (Baltimore); 2022 Sep; 101(37):e30610. PubMed ID: 36123865
[TBL] [Abstract][Full Text] [Related]
48. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
[TBL] [Abstract][Full Text] [Related]
49. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
50. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
[TBL] [Abstract][Full Text] [Related]
51. Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.
Liu QQ; Sun HF; Yang XL; Chen MT; Liu Y; Zhao Y; Zhao YY; Jin W
Cancer Med; 2019 Jun; 8(6):2840-2857. PubMed ID: 31016890
[TBL] [Abstract][Full Text] [Related]
52. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
[TBL] [Abstract][Full Text] [Related]
53. The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
Zhang L; Tang R; Deng JP; Zhang WW; Lin HX; Wu SG; He ZY
BMC Cancer; 2020 Nov; 20(1):1146. PubMed ID: 33238939
[TBL] [Abstract][Full Text] [Related]
54. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.
Cuyún Carter G; Mohanty M; Stenger K; Morato Guimaraes C; Singuru S; Basa P; Singh S; Tongbram V; Kuemmel S; Guarneri V; Tolaney SM
Cancer Manag Res; 2021; 13():6537-6566. PubMed ID: 34447271
[TBL] [Abstract][Full Text] [Related]
56. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement.
Liu Y; He M; Zuo WJ; Hao S; Wang ZH; Shao ZM
Front Oncol; 2021; 11():585613. PubMed ID: 33898305
[TBL] [Abstract][Full Text] [Related]
57. Prognostic role of radiotherapy in low-risk elderly breast cancer patients after breast-conserving surgery: a cohort study.
Lai X; Han W; Zhang H; Hou J; Wang G; Luo X; Li X; Wang Q; Zhang Y; Wang H; Li Y
Gland Surg; 2022 May; 11(5):847-859. PubMed ID: 35694094
[TBL] [Abstract][Full Text] [Related]
58. Incorporation of biologic factors for the staging of de novo stage IV breast cancer.
He ZY; Lian CL; Wang J; Lei J; Hua L; Zhou J; Wu SG
NPJ Breast Cancer; 2020; 6():43. PubMed ID: 32964117
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
60. The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer.
Park WK; Nam SJ; Kim SW; Lee JE; Yu J; Ryu JM; Chae BJ
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
